Patent Application
20230410956
The present invention is a data structure which supports one or more clinical studies enhancing and coordinating the creation of such clinical studies, the distribution of the clinical studies (both internal to registered users, clinicians, participants, fiscal participants, and external to the public at large), and provides a data structure facilitating fiscal support for the clinical studies. In one embodiment, smart contracts on a blockchain or distributed ledger technologic (DLT) system rewards clinicians, clinics, and patients who participate in clinical studies, and then further rewards clinical reviewers, follow-on patent participators, further clinical studies, and funders who support the clinical reports. If the clinical study is a success (success measured and monitored by the smart contract on the NFT blockchain), based upon public response to the publicly published clinical study report, the NFT blockchain is closed with, if available, a revenue distribution from sale of the study or the underlying study data. The registered users, clinicians, participants and fiscal participants are rewarded by distribution of funds related to the published clinical study.
It is well known that clinical studies are regularly conducted to determine the efficacy of drugs, drug regimens, medical devices, and other non-medical items, such as botanical compounds, nutritional compounds, and components. Society benefits from all these clinical studies. Although reference is made herein the clinical studies conducted by healthcare professionals, the invention is not limited to human studies nor healthcare professionals. The reference to “patients” applies equally to animals because such animals are subjects of the clinical studies.
One longstanding issue is how to increase patient participation in the clinical study. Many patients are not compensated for participating in such studies and, as a result, some of the patients may not regularly engage with the clinicians operating and conducting the clinical study. This is particularly true regarding botanical and nutritional compounds and compositions.
Another issue is funding studies at intermediate times during the patient data collection and prior to the final release of the clinical study report.
The present invention monitors patient participation and, if the clinical study deemed to be success, based upon objective and demonstrable guidelines, patients who participate and engage in the study are fiscally rewarded. Of course, it is often times difficult to obtain fiscal support for clinical studies. The present invention provides a structure and a framework to enable fiscal participants to support studies and, if the clinical study is deemed a success, fiscally rewarded. Although success is sometimes difficult to determine, by providing additional incentives, such as participation points, to participants engaged in the study when those participants review a private version of the clinical study, provide edits and comments to that private or internal clinical study, the quality and success of the study and the underlying abstract for the clinical study report improves. In addition, by providing further participation points to engaged participants who aggressively publicly distribute and comment on public version of the clinical study, this participation reward further increases probability of success. Success may be measured in several manners such as by sale of the clinical study report, collecting fees for accessing the online public clinical report, and selling the underlying raw data (which has been scrubbed of personal identifying information PII) to other companies in the field of study.
It is an object of the present invention to provide incentives for patient participation in clinical studies.
It is another object of the present invention to provide, in some cases, fiscal reward not only to fiscal participants but also patient participants, clinicians who gather the patient data for the report, drafted the report, edit the report, and publish the report.
It is a further object of the present invention to provide, in some cases, fiscal reward to participants who promote both internally and externally (an external event being classified as a public event) by distributing the initial or private clinical study report and also distributing the follow-on public study report on a public data structure, such as the Internet.
Although the invention is illustrated and described herein as embodied in a data structure supporting clinical study creation, distribution and fiscal components, it is, nevertheless, not intended to be limited to the details shown because various modifications and structural changes may be made therein without departing from the spirit of the invention and within the scope and range of equivalents of the claims. Additionally, well-known elements of exemplary embodiments of the invention will not be described in detail or will be omitted so as not to obscure the relevant details of the invention.
Other features that are considered as characteristic for the invention are set forth in the appended claims. As required, detailed embodiments of the present invention are disclosed herein; however, it is to be understood that the disclosed embodiments are merely exemplary of the invention, which can be embodied in various forms. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one of ordinary skill in the art to variously employ the present invention in virtually any appropriately detailed structure. Further, the terms and phrases used herein are not intended to be limiting; but rather, to provide an understandable description of the invention. While the specification concludes with claims defining the features of the invention that are regarded as novel, it is believed that the invention will be better understood from a consideration of the following description in conjunction with the drawing figures, in which like reference numerals are carried forward. The figures of the drawings are not drawn to scale.
Before the present invention is disclosed and described, it is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. The terms “a” or “an,” as used herein, are defined as one or more than one. The term “plurality,” as used herein, is defined as two or more than two. The term “another,” as used herein, is defined as at least a second or more. The terms “including” and/or “having,” as used herein, are defined as comprising (i.e., open language). The term “coupled,” as used herein, is defined as connected, although not necessarily directly, and not necessarily mechanically. The term “providing” is defined herein in its broadest sense, e.g., bringing/coming into physical existence, making available, and/or supplying to someone or something, in whole or in multiple parts at once or over a period of time.
In the description of the embodiments of the present invention, terms such as “first”, “second”, “third” and so on are only used for descriptive purposes, and cannot be construed as indicating or implying relative importance. It should be noted that, unless otherwise clearly defined and limited, terms such as “coupled”, or “connected” should be broadly interpreted, for example, it may be electrically or functionally connected (such as with software); it may be directly connected, or may be indirectly connected via an intermediate medium or one or more software or program modules. The terms “program,” “software application,” “APP,” “software” and the like as used herein, are defined as a sequence of instructions designed for execution on a computer system. A “program,” “computer program,” or “software application” or APP may include a subroutine, a function, a procedure, an object method, an object implementation, an executable application, an applet, a servlet, a source code, an object code, a shared library/dynamic load library and/or other sequence of instructions designed for execution on a computer system. Those skilled in the art can understand the specific meanings of the above-mentioned terms in the embodiments of the present invention according to the specific circumstances.
Conjunctive language such as the phrase “at least one of X, Y, and Z,” unless specifically stated otherwise, is otherwise understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z. Thus, such conjunctive language is not generally intended to imply that certain embodiments require at least one of X, at least one of Y, and at least one of Z to each be present.
The accompanying figures, where like reference numerals refer to identical or functionally similar elements throughout the separate views and which together with the detailed description below are incorporated in and form part of the specification, serve to further illustrate various embodiments and explain various principles and advantages all in accordance with the present invention. Further objects and advantages of the present invention are found in the detailed description and in the accompanying drawings.
The present invention is a data structure which supports one or more clinical studies enhancing and coordinating the creation of such clinical studies, the distribution of the clinical studies (both internal to registered users, clinicians, participants, fiscal partners, and external to the public at large), and provides a data structure facilitating fiscal support for the clinical studies.
The present invention relates to a blockchain system with smart contracts to reward clinicians, clinics, and patients who participate in clinical studies, and then further rewards clinical reviewers, follow-on patent participators, further clinical studies, and funders who support the clinical reports. If the clinical study is a success, success being monitored and measured by the NFT blockchain system, then the clinical study report is publicly published and the NFT blockchain is closed with, if available, distribution of revenue from the study. Some abbreviations used in the drawings are set forth in the Abbreviations Table near the end of this specification.
The invention employs a Web 3.0 format and data structure to provide a collaboration among persons and institutions (often unaffiliated with each other) for medical and clinical research. Today's clinical study environment is siloed with pharma companies keeping clinical study data and knowledge close to the vest. A blockchain collaboration allows decentralized, collaborative associations, with contributions by diverse participants working toward a project conclusion that is beneficial to scientific progress and beneficial to the contributing collaborators. For example, multiple clinical studies can be carried out by clinics which are widely geographically separated. The smart contract, blockchain format of the present invention keeps both clinical study (CL) data and data and engaged party activities (those who participate in the clinical study CL) well organized and functional in a Web 3.0 way. To the extent these collaborations get formed, they can absorb financial contributions, research and operational contributions, including an administration among diverse, but like-minded participants.
The blockchain function “L-FNC 112” at cell block 7 is discussed later in connection with
As for the blockchain in
Operationally, the blockchain includes one or more smart contracts which cooperate with oracles (data monitoring and input modules that gather data) and these embedded smart contracts in the blockchain include functions that generate the results described herein. The operation of the smart contract or contracts sets forth the agreement(s) or ground rules between collaborators interacting with the blockchain. It should be noted that the invention encompasses a high degree of flexibility in format, inputs, functional operations by one or more embedded smart contracts, and outputs. The descriptions of the operation herein are only exemplary of various operational aspects. For example, the financial outputs in
Returning to
In
Although the invention is particularly described above, the concept is not limited to NFT blockchains. The present invention is a method of operating a data structure to support a clinical study CL. A plurality of patients PAT participate in the clinical study and one or more healthcare clinicians conduct the study by engaging with and monitoring the clinical trial patients. Data is compiled in DB1, 2, and 3. Also, one or more fiscal participants (not specifically shown in
The invention operates on an internal or controlled data structure and an external, data structure, sometimes referred to as a public data structure. One example of a public data structure is the internet. The internal or controlled data structure (block 44,
In general, there are internal interactions (event block 42,
Progressing from
Further in
BLK-L8 Function obtains, at time T-8, for each member of the public who wishes to see the CLS report, PII data. This data is stored in the UPP database for the access-controlled data structure. Block BLK-L9 Function, at time T-9, monitors the number of views and interaction of the public with CLS report and the abstract interaction of the public in connection with the CLS abstract. This is event 30 which monitors previews of the CLS content. Function Update CPI, at time T-10, indicates that the blockchain is compiling data showing the importance (or lack of importance) of the abstract or the clinical study report (CLS report) in the public sphere.
Following the blockchain configuration of this specific embodiment to time T-11, Functions “FNC-” monitor the external promotion efforts by patients (PAT), clinicians, content CNT creators, ORR (outside reviewers, revisors or commentators), and financiers (fiscal participants), of the CLS report and the earlier published abstract. Also, the function at time T-11 documents internal participation by PAT and HC providers who drafted or participated in the CL studies. For example, if patients, who initially participated in the report, share the CLS report on social media and other websites, this external participation is documented in BLK-L10. As discussed later, the promoting PAT or participant or CNT creator is assigned points for each such promotional events. Internal participation in BLK-L10, time T-11, is, for example, further PAT follow-on studies, and published CLS report reviews by ORR (outside reviewers) on the internal, access-controlled data structure. Stated otherwise, if a participating patient discovers in outside or external review ORR of the CLS report and then copies or posts this external review on the access-controlled data structure, that participating patient or engaged participant is awarded additional points for this internal activity of posting and external review.
At time T-8, the NFT gathers UPP data on all new NFT token owners. At time T-9, the NFT captures data showing how many people view the now public CLS report. Typically, this is CPI data. At time T-10, the NFT updates the CPI data store and count. This CPI data store can be maintained on the blockchain or in the MSTR DB 12,
At the time T-13, BLK-L12, points are locked or stored into the blockchain. At time T-13, BLK-L13, mints NFT tokens based upon the point compiler output and NFT point thresholds. The NFT thresholds are point conversion tables. Additional blocks are minted at BLK-L14. In other words, it may take some time for the preview of the CLS report to become known and become a matter of public interest. BLK-L13 contemplates that the smart contract in the blockchain cell L13 monitors the performance of the clinical study report and the monetization of the same. The pay-per-view initial setting may be altered dependent upon the performance of the clinical study reports based upon CPI or external comments or reviews or traction on Twitter or Facebook social media platforms. Ad revenue can also be monitored by the smart contract in the specific blockchain, cell L13 contemplates that monitoring, generation or minting of additional NFT tokens. Others who wish to review the CLS report may either (a) be a qualified ORR (a qualified ORR may be a person who wishes to become an engaged participant or a registered participant based upon his or her interest in the clinical study which is documented by the qualified person completing the user personal profile UPP by the access-controlled data structure) or (b) pay for a full version of the CLS report. At time T-15, the an NFT smart contract “close” function is activated which determines whether the clinical study report has garnered enough interest to result in the sale of the CLS report to some third party or, more particularly, the sale of CLS 1, 2 and 3 clinical data, and hence to qualify as a “success”. Alternatively, the clinical report may not have generated sufficient interest. Sufficient interest maybe: follow-up patient participation, or use/views on the Internet or social media, or NFT financing (see
In a more general sense, after the internal interactions, the system and method releases, to the public data structure, a public version of the abstract which is “subject to” the internal distribution of the abstract. The abstract may be a preview of the formal CLS report. For example, the internal distribution may suggest changes to the abstract based upon comments, edits, or criticisms. These internal interactions are monitored and participation points Pts are awarded to the interacting parties. Once the abstract or preview is on the public data structure (which may be the Internet or limited private network), engaged participants (sometimes called registered participants) are assigned external abstract participation points (xAPP) based upon individual efforts of those engaged participants who have external abstract interactions (EAI) with the public abstract. These EAIs can be comments, edits, criticisms, or an EAI distribution act. After the public abstract is released, a public clinical study report is released. Hence, the system and method releases to the public data structure the public clinical study report subject to the internal distribution of the clinical study report. Again, the public clinical study report may include edits or responses to internally created content (CNT) comments, edits, or criticisms. External report participation points (xRPP) are assigned the interacting parties based upon individual efforts of the engaged participants who have an external report interaction (ERI), that is an ERI comment, an ERI edit, an ERI criticism, or an EM distribution act.
The system and method assigns either prior to, during, or after the clinical study, or whenever a fiscal participant engages to fiscally support the clinical study, an ownership interest unit (OIUs), from a plurality of ownership interest units, to the engaged fiscal participant (who may be one of many fiscal participants) on a fiscal pro rata basis. The system may cap the number of OIUs, or not, dependent upon a scarcity characteristic determined prior to the launch of the CLS data structure. A DLT data structure and a DAO data structure can be configured in a similar manner. In other words, a unit of ownership is assigned to fiscal participants based upon their respective financial investment in the clinical study venture.
In addition to ownership interest units OIUs assigned to fiscal participants, the points garnered by engaged/registered participants, clinicians, and clinical patients are converted into one or more ownership units based upon a predetermined point-to-unit conversion. The points are participation Pts, clinician Pts, fiscal Pts, APP, RPP, xAPP, and xRPP. In this manner, the fiscal participants are rewarded if the clinical report is favorable, and the patients, the clinical participants, and all other engaged participants are rewarded and hence motivated to collect more points by participation, drafting, editing, reviewing, commenting on, and sharing the abstract as well as the internal and the external or public discussions and further distribution (internally and externally on the public data structure (possibly the Internet)) and are rewarded by assignments of one or more ownership units OIUs based upon a predetermined point-to-unit conversion.
A smart contract, operating on the controlled data structure and on the public/internet data structure, determines success of the public clinical study report by monitoring performance interest on the public data structure (CPIs and social media indicators) when performance interest exceeds a predetermined threshold. Performance interest can be measured in several ways, such as by cpi (clicks per 1,000 views), offers to buy, critical commentary, laudatory commentary, etc. If the preprogrammed smart contract determines success, then engaged/registered participants are fiscally rewarding based upon their ownership units. Points are converted to OIUs by a conversion plan and program.
Further enhancements include assigning patient participation points (PPP) to each patient for their individual effort in the clinical study, and, to reward clinicians, the clinician Pts are differentiated from engaged participant Pts and from PPP. Fiscal Pts (FP) are also differentiated from both clinician Pts and patient participation points PPP. In this manner, work by clinicians is rewarded at a higher level than patient Pts. The controlled data structure is communicatively coupled to the internal data structure and the public data structure to conduct monitoring and distribution. This may be an autonomous operation. All functions may be autonomous.
As such, the controlled data structure may include one of a blockchain, a non-fungible token (NFT) blockchain, and a distributed ledger technologic (DLT) structure. Prior to granting access to the controlled data structure, engaged participants provide personal identifying information (PII) to a user personal profile (UPP) data store on the controlled data structure and access to the controlled data structure is provided by a respective access pass assigned to each engaged participant. Also, non-participants may sign up with the controlled data structure. The plurality of non-participants who are interested in the clinical study are sometimes called incipient engaged participants. The system and method gathers PII from the incipient engaged participants for the UPP data store. Once the PII is uploaded to the UPP data store, each incipient engaged participant defined as an engaged or registered participant.
As another enhancement of the invention, interaction with an engaged participant is rewarded by assigning a general participation point (GPP) to each engaged participant: (m) who interacts with the internally distributed abstract, (n) who interacts with the internally distributed clinical study report, (o) who interacts with the public abstract, and (p) who interacts with the public clinical study report. The a general interaction (GI) is one or more of a GI comment, a GI edit, a GI criticism, or a GI distribution act. The system differentiates GPP from clinician Pts, patient participation points PPP, and fiscal Pts (FP) because the GI interactions are less valuable to the success of the CLS study. However, GI interaction rewards, which are open to the public, do advance the success of the overall CLS program. The conversion of participating Pts into one or more ownership units OIUs includes converting GPP points into one or more OIUs based upon the predetermined point-to-unit conversion. The concept employed by the present invention is that the point system, which ultimately translates into OIU ownership claims can be varied based upon: (a) the skill level of the person delivering the service to the CLS data structure; (b) the CLS demand for patients suffering from certain conditions or having a condition within the bounds of the CLS study (that is, a supply of patients who generate useful data); and (c) the time and effort expended by the participating person. Understandably, factors 1 and 3 are on a sliding scale and the point system presented herein cannot cover nor address all CLS studies, or, for that matter, all curated content (CNT) as discussed in connection whit
Another configuration of the system and the method is a data structure supporting a clinical study by monitoring patient participation (patient Pts or PPP), assigning points for the clinical study (that is, giving points to the clinicians (CPP points) gathering patient data, then drafting the abstract, then drafting the clinical study report, responding to suggestion and criticisms, etc. as explained above. Patient participation points (PPP) are assigned to each patient who participates. Clinician participation points (CPP) are assigned to each clinician who operates the clinical study, creates an abstract, creates the clinical study report. All this is based upon the respective clinician participation level. Fiscal points (FP) are assigned to each fiscal participant based upon individual's fiscal support of the clinical study. Other points are: internal abstract participation (APP points); internal abstract interaction (IAI points); internal report participation points (RPP); external abstract participation points (xAPP) (EAI interactions); external report participation points (xRPP) (based on ERI comments, edits, criticisms, and ERI acts of distribution). Ownership interest units OIUs are assigned fiscal participants based on FP points (essentially on a fiscal pro rata basis). The various Pts (PPP, CPP, FP, APP, RPP, xAPP, and xRPP) are converted into ownership units OIUs based upon a predetermined point-to-unit conversion plan. Further enhancements include: assigning an additive clinician participation point (xCPP) to each clinician (w) who interacts internally with abstract, (x) who interacts internally with clinical study report, (y) who interacts publicly with the abstract, and (z) who interacts publicly with clinical study report. The clinician interaction (CI) is mapped or based on CI comments, edits, criticisms, and CI distribution acts. The fiscal participation points FP may be assigned pre or post assignment of PPP points to patients or assignment of CPP to each clinician.
Further aspects of the invention include (a) uploading each patient's clinical study data into the controlled data structure (b) providing access from the controlled data structure to a public internet data structure (Internet) via a data communications module. The communications module is a communicative bridge function permitting certain blockchain initiated operations from the controlled data structure to be executed on the Internet or the public data structure. In other words, the smart contracts on the blockchain can monitor actions on the public data structure (typically, the Internet).
An important computer and data structure aspect of the present invention is to solve the problem of interim financing, that is, prior to the final public release of the CLS report. Fiscal participants cannot see or review interim clinical study data. However, the present data structure does permit internal, interim reports to be viewed by fiscal participants on a confidential basis. Patient data is masked by striping out PII. Interim CLS reports are internally circulated and subject to comment and criticism. Fiscal partners could review this data structure and decide to fund or not to fund when called upon by the clinical team. Therefore, the present invention is an improved computer data processing structure and method.
The system has a function FNC 42A monitoring the posting of online data by monitoring UPP-registered users (those having system user names) and logs user-generated comments, photos, video, reposting acts, likes, and dislikes. Most likely, given the clinical nature of the studies, a private web site or social media platform may be used to either promote the study or engage in patient participants providing feedback on treatment, success or, in some cases, failure. In some cases, completely open communication platforms (YouTube, twitter) may be integrated into the system.
The monitoring function used by the NFT blockchain can also be tied into the Internet ad network. See FNC 41. It is well known that the ad network provides funding for social media platforms as well as some websites by presenting ads to viewers of social media content CNT and web site content CNT.
The smart contract can give “participation points” to patients, which are akin to loyalty points. The loyalty points can be redeemed as free admission to educational seminars (these being utility tokens minted by the NFT blockchain, permitting admission to events, lectures, etc.); access to participate in the clinical study; and copies of the final report. The loyalty point program can be extended to any or all of the players and participants. The smart contract(s) can give % income shares (OIUs) to certain people (investors, clinicians who gather data; clinicians who draft the reports; clinicians who review/edit/approve the reports); and promoters (investors, clinicians who gather data; clinicians who draft the reports; persons who promote seminars during which the reports are discussed). There are many, many variations on the input and output of the smart contract. It is not feasible to outline all variations.
In
Patient points PAT-pts (Level 4, col. 4) are awarded because patient data is needed to generate not only the first CLS report but also follow-on CLS reports. CL-pts points (Level 5, col. 5) are established both for patients who complete the entire CLS data input cycle and are involved in the clinical studies as well as clinician activity in the clinical studies. CLS points are awarded for drafting the clinic clinical studies (Levels 6 and 7, col. 6 and 7).
The smart contract for a given clinical collaboration may bestow rewards on patients that participate e.g., by providing feedback on their physical conditions and effect of the medical treatments administered on them in the trials.
As an incentive to participate in the CL study or promote the CLS abstract or CLS study even as a viewer, the point calculator in Level 8, (col. 8), shows an award of some points when the person or entity joins the CLS blockchain system. Once a user completes a an UPP in the system, see event 46 in FIG. 3A, the NFT CLS system can track such user and award points for viewing content CNT. Each new engaged or registered participant, per conversion function Level 8, is awarded 5 points. In Level 9 (col. 9), a CLS report funding or fiscal action is noted. Some persons may wish to fiscally invest in the NFT or the CLS report and this funding is rewarded by assignment of OIUs, via the point system by converting the amount of funds provided to the system and to a point-based system. The shown value in
The system may tokenize points by minting a OIU NFT token or by giving a reward to participants (a utility token). These NFT awards could occur at intervals, upon specified events or milestones or time-frames, at the conclusion of the clinical trial, or after a final evaluation and allocation is made consistent with the smart contract rules. The smart contract establishes the rules for all participants based upon interactions of any nature: (i) issuance of OIU NFT tokens representing % income; (ii) issuance of loyalty or reward points; or (iii) giving a utility token (such as a “social club admission” or access to educational events) reward to qualifying participants. The term “NFT Participant” refers to all the players in the NFT clinical scheme. Any output from the NFT (that is, any reward/$/social club access), could occur at intervals, upon specified events locked into the NFT smart contract, or milestones monitored by the NFT smart contract, at the conclusion of the clinical trial, or after a final evaluation.
The following Abbreviations Table provides brief, but not complete, explanations of abbreviations used in the drawings.
There are many ways of designing a point system for the clinical study. The following Chronologic Point Table expands upon the basic theories set forth above and sets forth additional participation points based upon the following Time Events: Gather Clinical Data at Clinic (CL); Draft CLS Rpt (CL Study (CLS) Rpt: internal action); Published Abstract (Abstr); Published CL Rpt on NFT external monitored platform; and CLS Rpt Published Internal Action on CLS NFT monitored platform. Hence, internal or on-platform interactions can occur at the same as external interactions.
The following Condensed Point and Abbreviations Table also has certain abbreviations used to differentiate points in the examples.
Blockchain cell 55, BLK-L202, monitors external promotion event 52 in the network promotion event 54, engages in the conversion program discussed earlier, and issues OIUs based on the conversion of points. Points include internal or on-platform interactions, comments, reviews, internal distribution efforts, internal promotion of the CNT, etc. Points also include external or off-platform interactions, comments, reviews, external distribution efforts, external promotion of the CNT, etc. Cell 57, BLK-L203, and event 56 monitors internal interaction and assigns participation points to that internal interactional events by engaged or registered participants. Cell 59, BLK-L204, engages a full close out function or a partial close out function of the CNT. The CNT is subject to limited access by its functional relationship to the NFT and access controlled data structure. A full close out may be a complete sale of the CNT and release of all rights to that content. In this manner, as shown event the 58, the sale involves curated or popular content which has been vetted, reviewed, promoted and distributed potentially on a limited basis to NFT engaged participants. A partial close out would sell some of the rights the content CNT but retain some participation rights by existing NFT owners holding OIUs. As noted in
Event 68 is the final curation of the CNT and cell 69, BLK-L304, monitors the final curation of the CNT. Event 70 and cell 71, BLK-L305, engages and executes a close out function. This close out function may involve an ad campaign based upon the internal data collection and the external data collection by the engaged or registered participants from events 62, 64, 66 and 68. The close out function in event 70 may have various characteristics as discussed above. Event 72 indicates that the content CNT and all rights to that CNT have been sold by the blockchain developer and the developer has received some fiscal renumeration. Cell 71, operating a smart contract, distributes that fiscal renumeration to NFT owners pro rata based upon their OIU ownership.
As used herein, the term “fiscal” refers to or relates to a financial aspect of the clinical study or the curated content CNT discussed in connection with
As for the Internet being a data structure, some commentators describe the Internet as a public data structure because data structures are the organizational tools data scientists use to update, manage and index internet services efficiently. Data structures are also algorithmic systems, due to the way the algorithmic systems filter and sort large quantities of data. There are three main parts to a data structure that make it work: (i) the Memory Address: The fixed raw data element of any desired feature or function; (ii) The Pointer: A reference tool that represents the location of a memory address; and (iii) The Procedure: A written code that manipulates or creates different functions inside the structure, either automatically or manually. The pointer, the memory address and the procedures of a data structure are important, as the use of them, or the way that they are represented in any given database or website, determines the different types of data structures a database can fall into.
As described above, the inventions relies upon and uses software or computer implemented embodiments. The terms “program,” “software application,” “APP” and the like as used herein, are defined as a sequence of instructions designed for execution on a computer system. A “program,” “computer program,” or “software application” may include a subroutine, a function, a procedure, an object method, an object implementation, an executable application, an applet, a servlet, a source code, an object code, a shared library/dynamic load library and/or other sequence of instructions designed for execution on a computer system. Those skilled in the art can understand the specific meanings of the above-mentioned terms in the embodiments of the present invention according to the specific circumstances. Further, although sequential steps are discussed in connection with the embodiments of the invention, the steps and processes may be re-ordered for efficiency or other reasons apparent to those skilled in the art. Additionally, although NFTs and blockchains are discussed in connection with embodiments of the present invention, the invention is not so limited to those types of data structures. Stated otherwise, a comprehensive computer program or groups of computer programs may be designed to fulfill the functions and processes described and claimed herein. In this sense, the invention is not limited to NFTs, blockchains, DLT systems or DAO systems.
The claims appended hereto are meant to cover modifications and changes within the scope of the present invention. What is claimed is:
This non-provisional patent application is based upon and claims the benefit of provisional patent application Ser. No. 63/351,465, filed Jun. 13, 2022, now pending, the contents of which is incorporated herein by reference thereto.
| Number | Date | Country | |
|---|---|---|---|
| 63351465 | Jun 2022 | US |
